THIS WEEK IN THE PUBLIC INDEX
本周收录 · AI 生物制药与虚拟生命科学
2026-10-05 — 2026-10-08 · 北京时间周一 00:00 至页面生成时的公开原文概要。
当前公开收录 95 条
行业原文 51 条 · 精选期刊 AI 主题研究 44 条 · 有收录的来源 14 个。
窗口起点 2026-10-04T16:00:00.000Z，生成时间 2026-10-08T12:53:08.529Z（UTC）；上方日期按北京时间展示。计数在列表限额之前计算，使用公开资源去重规则。撤销来源或调整公开范围后，计数和列表会重新计算。
主题为自动检索分类，同一原文可进入多个主题。零表示当前收录窗口没有公开符合条件的条目，不表示行业没有发生进展。
本周收录的原文与出处
显示最新 30 条，最多 30 条；完整统计为 95 条。每条直接连接本站记录和原始出处。
Diffusing protein binders to intrinsically disordered proteins
Crossref REST API · 学术索引收录 · 来源发布：Wed Jul 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 11:07:46 GMT+0000 (Coordinated Universal Time)
Abstract Proteins that bind to intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) with high affinity and specificity could be useful for therapeutic and diagnostic applications 1–4 . How
Computational design of metallohydrolases
Crossref REST API · 学术索引收录 · 来源发布：Wed Dec 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 11:07:46 GMT+0000 (Coordinated Universal Time)
Abstract De novo enzyme design seeks to build proteins containing ideal active sites with catalytic residues surrounding and stabilizing the transition state(s) of the target chemical reaction 1–7 . The generative artifi
AlphaFold ‘goes viral’: database adds protein complexes of common viruses
Crossref REST API · 学术索引收录 · 来源发布：Thu Sep 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 11:07:46 GMT+0000 (Coordinated Universal Time)
AlphaFold ‘goes viral’: database adds protein complexes of common viruses
Sampling protein language models for functional protein design
Crossref REST API · 学术索引收录 · 来源发布：日期未提供 · 本站收录：Thu Oct 08 2026 09:31:31 GMT+0000 (Coordinated Universal Time)
Sampling protein language models for functional protein design
Robust out-of-distribution prediction of Buchwald–Hartwig reactions
Crossref REST API · 学术索引收录 · 来源发布：Mon Aug 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:29:04 GMT+0000 (Coordinated Universal Time)
Abstract The Buchwald–Hartwig cross-coupling is a cornerstone of modern pharmaceutical synthesis, yet predictive modeling of its outcomes remains constrained by data quality and chemical space coverage. Electronic labora
Multistate and functional protein design using RoseTTAFold sequence space diffusion
Crossref REST API · 学术索引收录 · 来源发布：Wed Sep 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:21:33 GMT+0000 (Coordinated Universal Time)
Abstract Protein denoising diffusion probabilistic models are used for the de novo generation of protein backbones but are limited in their ability to guide generation of proteins with sequence-specific attributes and fu
Atomically accurate de novo design of antibodies with RFdiffusion
Crossref REST API · 学术索引收录 · 来源发布：Wed Nov 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:15:50 GMT+0000 (Coordinated Universal Time)
Abstract Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization
De novo designed proteins neutralize lethal snake venom toxins
Crossref REST API · 学术索引收录 · 来源发布：Wed Jan 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:15:48 GMT+0000 (Coordinated Universal Time)
Abstract Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more 1,2 . Three-finger tox
Engineering human multi-organ tissue chip niches for drug absorption, distribution, metabolism, excretion and toxicity prediction.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:29 GMT+0000 (Coordinated Universal Time)
Predicting human drug responses in vitro remains a central challenge in drug development. Animal models have shown limited accuracy in recapitulating human drug absorption, distribution, metabolism, excretion and toxicit
Owkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New Collaboration
Owkin official newsroom · 行业原文收录 · 来源发布：Thu Aug 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:24 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kogniti
Isomorphic Labs announces $600m external investment round
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Mon Mar 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:23 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital fro
CytoVI: deep generative modeling of antibody-based single cell data.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Antibody-based single-cell technologies, such as flow cytometry, mass cytometry and CITE-seq, have become widely used in clinical diagnostics and basic research; however, their analysis is complicated by technical noise,
FLIGHTED: Inferring fitness landscapes from noisy high-throughput experimental data.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Fri Oct 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Machine learning (ML) for protein design requires large protein fitness datasets generated by high-throughput experiments for training and benchmarking models. However, most models do not account for experimental noise i
Function-preserving watermarking of AI-generated proteins.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:22 GMT+0000 (Coordinated Universal Time)
Generative artificial intelligence (AI) models are revolutionizing biology, with tools such as AlphaFold 3 and protein design models accelerating breakthroughs in protein structure prediction and the creation of new func
Owkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research
Owkin official newsroom · 行业原文收录 · 来源发布：Fri Aug 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:15 GMT+0000 (Coordinated Universal Time)
PARIS & PORDENONE, Italy — Owkin, the agentic AI company pioneering the first autonomous AI scientist to revolutionize drug discovery and development, and the Centro di Riferimento Oncologico di Aviano (CRO), a leading I
Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:09:05 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs appoints Dr. Ben Wolf M.D., Ph.D., as Chief Medical Officer and establishes US Presence. Dr. Wolf will be based in the company's newly established Cambridge location, where
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · 行业原文收录 · 来源发布：Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together
Isomorphic Labs to appoint Max Jaderberg as President
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Wed Nov 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:54 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces the appointment of Max Jaderberg as President of the company effective 1 January 2026, transitioning from his current role as Isomorphic Labs’ Chief AI Officer. Co
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin official newsroom · 行业原文收录 · 来源发布：Fri Sep 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:48 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - September 11, 2026 — Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent
Iambic Named to CNBC Disruptor 50 for Second Consecutive Year
Iambic official newsroom · 行业原文收录 · 来源发布：Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:47 GMT+0000 (Coordinated Universal Time)
San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recogniz
Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Tue Jan 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:46 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces a cross-modality, multi-target research collaboration with Johnson & Johnson. This partnership brings together Iso’s AI-first approach to drug discovery with Johns
Machine learning for functional protein design.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Feb 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Recent breakthroughs in AI coupled with the rapid accumulation of protein sequence and structure data have radically transformed computational protein design. New methods promise to escape the constraints of natural and
A Generative Neural Network for Maximizing Fitness and Diversity of Synthetic DNA and Protein Sequences.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Jun 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Engineering gene and protein sequences with defined functional properties is a major goal of synthetic biology. Deep neural network models, together with gradient ascent-style optimization, show promise for sequence desi
AI-enhanced adaptive virtual screening of large libraries for ligand discovery.
Europe PMC REST API · 学术索引收录 · 来源发布：Tue Sep 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Ultralarge virtual screenings (ULVSs) evaluate billions of molecules for drug discovery but face cost, flexibility and scalability limits. We introduce AdaptiveFlow, an open-source platform that makes ULVSs more accessib
Artificial intelligence for natural product drug discovery.
Europe PMC REST API · 学术索引收录 · 来源发布：Mon Sep 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:43 GMT+0000 (Coordinated Universal Time)
Developments in computational omics technologies have provided new means to access the hidden diversity of natural products, unearthing new potential for drug discovery. In parallel, artificial intelligence approaches su
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · 行业原文收录 · 来源发布：Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their t
Bayer and Iambic collaborate to advance drug discovery with AI
Iambic official newsroom · 行业原文收录 · 来源发布：Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:35 GMT+0000 (Coordinated Universal Time)
Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’
Isomorphic Labs announces Series B investment round
Isomorphic Labs official announcements · 行业原文收录 · 来源发布：Tue May 12 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:33 GMT+0000 (Coordinated Universal Time)
Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $2.1 Billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alon
The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development.
PubMed / NCBI E-utilities · 学术索引收录 · 来源发布：Thu Sep 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:33 GMT+0000 (Coordinated Universal Time)
Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled
Binding and sensing diverse small molecules using shape-complementary pseudocycles.
Europe PMC REST API · 学术索引收录 · 来源发布：Thu Jul 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:08:29 GMT+0000 (Coordinated Universal Time)
We describe an approach for designing high-affinity small molecule-binding proteins poised for downstream sensing. We use deep learning-generated pseudocycles with repeating structural units surrounding central binding p
本周日期内的已核验事件
3 条，显示最多 10 条。优先按发生日期，缺失时按公告日期；此口径与上方按收录时间统计的原文不同。
Isomorphic Labs 加入 Virtual Biology Initiative
Wed Oct 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Isomorphic Labs 官方公告，加入由 Biohub 召集的 Virtual Biology Initiative，参与组织将投入数据、计算与测量技术。Biohub 尚未完成本库实体归属核验，暂不绘制关系边。
晶泰公布 XGlue 分子胶平台与临床前管线进展
Tue Oct 06 2026 03:29:09 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据晶泰官方 RSS 中的公告，XGlue 工作结合计算与实验数据训练 AI 模型，对 E3 与目标蛋白组合进行优先级判断；不把公司表述转换为临床疗效证据。
Iambic 提交第二款自有 AI 发现候选药 IAM217 的 IND
Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 条当前公开证据
据 Iambic 官方公告，已提交 IAM217 的 IND 申请。提交申请不等于监管批准，也不代表临床疗效已获证实。
专题指南：从原文到判断
按任务比较模型，按证据追踪合作；每篇保留原始出处与更新日期。
虚拟细胞、AI 模型与公司：应该怎样比较？
按输入、输出、任务和验证条件比较单细胞模型、结构预测与蛋白设计，并区分模型论文与公司能力。
阅读指南 · 更新 2026-10-08
AI 制药公司合作时间线：从公告读到证据
用真实官方公告区分合作主体、首付款、条件性里程碑和研发进度，并建立可追溯的合作时间线。
阅读指南 · 更新 2026-10-08
每周 AI 制药信息怎么读：公司动态、研究进展与覆盖缺口
建立每周阅读顺序，分清公告、论文与临床结果；理解本站本周收录的时间窗口、分母和来源覆盖。
阅读指南 · 更新 2026-10-08